PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.68M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
66.40%
Revenue growth above 1.5x CVE's 14.09%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
139.84%
Gross profit growth above 1.5x CVE's 13.16%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
337.00%
EBIT growth above 1.5x CVE's 26.09%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
337.00%
Operating income growth above 1.5x CVE's 26.09%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
237.14%
Net income growth under 50% of CVE's 1521.82%. Michael Burry would suspect the firm is falling well behind a key competitor.
222.00%
EPS growth under 50% of CVE's 1511.11%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
222.00%
Diluted EPS growth under 50% of CVE's 1511.11%. Michael Burry would worry about an eroding competitive position or excessive dilution.
13.06%
Share change of 13.06% while CVE is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
13.06%
Diluted share count expanding well above CVE's 0.02%. Michael Burry would fear significant dilution to existing owners' stakes.
-21.03%
Dividend reduction while CVE stands at 1.64%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
71.27%
OCF growth under 50% of CVE's 192.43%. Michael Burry might suspect questionable revenue recognition or rising costs.
175.36%
FCF growth under 50% of CVE's 790.43%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
-70.29%
Negative 10Y revenue/share CAGR while CVE stands at 26.17%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-30.56%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
246.05%
3Y revenue/share CAGR above 1.5x CVE's 32.08%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-74.80%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-36.62%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
569.07%
3Y OCF/share CAGR above 1.5x CVE's 321.77%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-23.55%
Negative 10Y net income/share CAGR while CVE is at 581.45%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-33.47%
Negative 5Y net income/share CAGR while CVE is 78.68%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
134.27%
Below 50% of CVE's 553.11%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-77.54%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-21.07%
Negative 5Y equity/share growth while CVE is at 12.53%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
25.10%
3Y equity/share CAGR above 1.5x CVE's 10.63%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-95.48%
Cut dividends over 10 years while CVE stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-73.17%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
39.31%
3Y dividend/share CAGR above 1.5x CVE's 0.11%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
5.50%
Our AR growth while CVE is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
No Data
No Data available this quarter, please select a different quarter.
0.29%
Positive asset growth while CVE is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-14.50%
We have a declining book value while CVE shows 9.36%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
2.84%
We have some new debt while CVE reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-12.74%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.